Paula Cannon

Reflecting on the evolution of gene therapy from good idea to mundane miracle

The financial and regulatory barriers to patient access, the field’s perceived image problem, and what it would take for policymakers to evaluate gene therapy with the same measured risk–benefit lens applied to other medicines are discussed.